These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 16403774

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
    Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ.
    Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
    Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Göke B, Katschinski M.
    Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
    [Abstract] [Full Text] [Related]

  • 5. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia.
    Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M.
    Crit Care Med; 2010 May; 38(5):1261-9. PubMed ID: 20228679
    [Abstract] [Full Text] [Related]

  • 6. The antagonistic metabolite of GLP-1, GLP-1 (9-36)amide, does not influence gastric emptying and hunger sensations in man.
    Nagell CF, Pedersen JF, Holst JJ.
    Scand J Gastroenterol; 2007 Jan; 42(1):28-33. PubMed ID: 17190759
    [Abstract] [Full Text] [Related]

  • 7. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
    Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B, Nauck MA.
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W.
    Regul Pept; 2004 Apr 15; 118(1-2):89-97. PubMed ID: 14759561
    [Abstract] [Full Text] [Related]

  • 13. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA.
    Diabetologia; 2002 Oct 15; 45(10):1410-5. PubMed ID: 12378382
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.
    Nicolaus M, Brödl J, Linke R, Woerle HJ, Göke B, Schirra J.
    J Clin Endocrinol Metab; 2011 Jan 15; 96(1):229-36. PubMed ID: 21047924
    [Abstract] [Full Text] [Related]

  • 19. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
    Nauck MA, Holst JJ, Willms B, Schmiegel W.
    Exp Clin Endocrinol Diabetes; 1997 Jan 15; 105(4):187-95. PubMed ID: 9285204
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.